GlassScriptPhysician profile
Stephanie R Lehrhoff
NPI 1164681193
$2,861.14
in general payments reported to CMS, 2019-2025
28 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $312 · 2022: $234 · 2023: $346 · 2024: $526 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.88 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $376.12 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $301.71 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $243.58 | 2020-2025 | Dupixent |
| Pfizer INC. | $205.52 | 2019-2025 | |
| Abbvie INC. | $197.11 | 2019-2025 | |
| Lilly USA, LLC | $179.21 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $167.72 | 2024-2025 | Zoryve |
| Ucb, INC. | $151.51 | 2024-2025 | Bimzelx |
| Incyte Corporation | $125.27 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $123.64 | 2019-2025 | Cabtreo, Jublia |
| Leo Pharma INC. | $117.57 | 2019-2025 | Anzupgo, Adbry |
| Amgen INC. | $96.24 | 2019-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $83.68 | 2023-2025 | |
| Galderma Laboratories, L.P. | $76.53 | 2019-2025 | |
| Dermavant Sciences, INC. | $68.72 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $65.83 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $53.85 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $39.61 | 2019-2025 | |
| Stemline Therapeutics INC. | $31.73 | 2019 | |
| Biofrontera INC. | $30.00 | 2019 | |
| Celgene Corporation | $28.93 | 2019 | |
| Verrica Pharmaceuticals INC. | $19.39 | 2024 | Ycanth |
| Revance Therapeutics, INC. | $17.06 | 2024 | Daxxify |
| Sandoz INC. | $15.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.30 | 2023 | Spevigo |
| Vyne Pharmaceuticals INC. | $14.09 | 2020 | |
| Merck Sharp & Dohme LLC | $12.24 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $3.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Lehrhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.